Landreneau Forging New Path for Mesothelioma Patients in Pittsburgh

Renowned thoracic surgeon Dr. Rodney Landreneau once hoped the number of pleural mesothelioma patients would have declined significantly by now — decades after the widespread use of asbestos dropped dramatically in America. But his hope never materialized. Landreneau, a mesothelioma and lung cancer specialist, and pioneer in treatment advances, remains in high demand today. Last month, he moved back to Allegheny General Hospital in Pittsburgh, where he helped carve his reputation as a surgical innovator 25 years ago. "Unfortunately, there still are a lot of patients being diagnosed with mesothelioma in this area," he told Asbestos.com recently. "We're back here to serve them now. We can help them. Advances have been made recently. There was a void that needed to be filled." Landreneau is one of the few surgeons in the nation performing the surgical debulking/hyperthermic chemoperfusion combination for mesothelioma patients. It involves removing all visible signs of cancer throughout the thoracic cavity before bathing it with heated chemotherapy drugs to kill any microscopic remains. Broke New Ground in Louisiana In 2013, he became the first surgeon to perform the procedure in Louisiana, where he quickly attracted mesothelioma patients to the Ochsner Cancer Center in New Orleans. He returned to Pittsburgh in October as co-director of the Esophageal and Lung Institute at Allegheny, where he worked before spending almost 20 years at the nearby Univers...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Conclusion: EUS-B-FNA is a feasible and safe technique for diagnosing centrally located intrapulmonary tumors that are located near or adjacent to the esophagus. EUS-B should be considered in the same endoscopy session following nondiagnostic bronchoscopy and EBUS.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
Dr. Chukwuemeka Ikpeazu at the Sylvester Comprehensive Cancer Center has brought hope — where once there was none — to patients in South Florida with unresectable pleural mesothelioma. Ikpeazu is the principal investigator in the multicenter phase II clinical trial involving the much-anticipated immunotherapy drug durvalumab. Pharmaceutical giant AstraZeneca manufactures the drug under the brand name Imfinzi. “I am optimistic, very, very optimistic that this drug will be effective for these patients,” Ikpeazu told Asbestos.com. “All the data, all the earlier studies, are encouraging.” He...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: - These proposals have been mostly accepted by the Union for International Cancer Control and the American Joint Committee on Cancer and incorporated into their respective staging manuals (2017). The Union for International Cancer Control recommended implementation beginning in January 2017; however, the American Joint Committee on Cancer has deferred deployment of the eighth TNM until January 1, 2018, to ensure appropriate infrastructure for data collection. This manuscript summarizes the updated staging of thoracic malignancies, specifically highlighting changes from the 7th edition that are relevant to path...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
In this study, we investigated podoplanin expression in 40 feline squamous cell carcinomas (14 cases of mouth floor, 13 of skin, 9 of ear, and 4 of tongue) by immunohistochemical analysis using an anti-cat podoplanin mAb PMab-52, which we recently developed by cell-based immunization and screening (CBIS) method. Of the total 40 cases, 38 (95%) showed positive staining for PMab-52. In particular, 12 cases (30%) showed a strong membrane-staining pattern of squamous cell carcinoma cells. PMab-52 can be useful for antibody therapy against feline podoplanin-expressing squamous cell carcinomas. PMID: 29090969 [PubMed - as supplied by publisher]
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
This study is the first report about secondary HOA caused by non-pleural or pulmonary tumors. Various primary tumors were identified, including several rare tumors such as sarcomas. HOA is a rare disorder with typically radiologically findings, which is not only associated with lung cancer or pleural mesothelioma and can even occur in tumor patients without lung metastasis.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Thoracic surgeon Dr. Raja Flores, like so many other patriotic Americans, rushed to help after the horrific 9/11 terrorist attack at the World Trade Center (WTC) in New York City. As the world prepares to commemorate the 15th anniversary of the 9/11 attacks, Flores’ work is far from done. While the memory of that fateful Sept. 11, 2001, is beginning to fade for many, the threat of a resulting and significant rise in mesothelioma cancer is looming large on the horizon. The alarming number of future mesothelioma cases will stem from the weeks-long rescue and cleanup efforts performed under the toxic cloud that containe...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: 15th anniversary 9/11 9/11 15 year anniversary 9/11 attack at world trade center 9/11 mesothelioma cases 9/11 terrorist attack asbestos after 9/11 attack asbestos in 9/11 attack Source Type: news
Thoracic surgeon Dr. Raja Flores believes an alarming number of asbestos-related diseases, such as mesothelioma, will start emerging soon in New York City, stemming from rescue and cleanup efforts after the historic 9/11 terrorist attack at the World Trade Center 14 years ago. He compared it to Libby, Montana, where hundreds of miners, family members and nearby residents have died or been sickened by the asbestos dust pouring from vermiculite mines decades ago. "I hope I'm wrong, but I don't think so," Flores, chief of thoracic surgery at Mount Sinai Medical Center in New York, told Asbestos.com. "We've se...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Legislation, Laws & Litigation Source Type: news
This study was one of the few that involved only "shipbreaking," which is the dismantling of old ships for salvage or scrap. It also examined cancers beyond mesothelioma, a cancer caused almost exclusively by inhalation or ingestion of asbestos. The study, published in the on-line medical journal PLOS One, was linked to the Taiwan Cancer Registry and involved 4,227 workers from the 1985 Kaohsiung Shipbreaking Workers Union who belonged to the Labor Insurance Program. They were followed until 2008. There were 940 deaths and 436 cancer cases reported. Their numbers were compared to a control group of 22,135 who wor...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news
Publication date: 20 July 2015 Source:Clinica Chimica Acta, Volume 447 Author(s): Bin Wei , Chunmei Guo , Shuqing Liu , Ming-Zhong Sun Annexin A4 (Anxa4) is one of the Ca2+-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis, and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemoresistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemoresistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC)...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Abstract Annexin A4 (Anxa4) is one of the Ca(2+)-regulated and phospholipid-binding annexin superfamily proteins. Anxa4 has a potential role in diagnosis, prognosis and treatment of certain cancers. Studies indicate that Anxa4 up-regulation promotes the progression of tumor and chemo-resistance of colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), endometrial carcinoma (EC), gastric cancer (GC), chemo-resistant lung cancer (LC), malignant mesothelioma (MM), renal cell carcinoma (RCC), ovarian clear cell carcinoma (OCCC), cholangiocarcinoma, hepatocellular carcinoma (HCC), breast cancer (BC) and la...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Esophagus Cancer | Health | Heart | Hospitals | Insurance | Lung Cancer | Lung Transplant | Mesothelioma | Transplants